Galenical formulations

US7025975B2 · kind B2 · utility

Assignee

• Novartis AG · CH

Inventors

• Gerd Fricker · Staufen, DE
• Barbara Haeberlin · Riehen, CH
• Armin Meinzer · Glückstadt, DE
• Jacky Vonderscher · Riedisheim, FR

Key dates

• Filing date: May 18, 2004
• Grant date: Apr 11, 2006
• Expiry date: May 18, 2024

Classification

• Technology area (CPC A): Human Necessities
• CPC primary: A61K47/44
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

A pharmaceutical composition containing macrolide, e.g. a rapamycin compound in an emulsion preconcentrate or microemulsion preconcentrate for oral administration. The carrier medium for the rapamycin compound includes a hydrophilic phase, a lipophilic phase and a surfactant. The composition is stable and provides high absorption efficiency.